Statistics for ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional
Total visits
| views | |
|---|---|
| ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional | 33 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 16 |
| October 2024 | 14 |
| November 2024 | 3 |
File Visits
| views | |
|---|---|
| REVISION_RAPIDA_042_2021 | 15 |